標(biāo)題: Titlebook: Resistance to Targeted Therapies in Breast Cancer; Jenifer R. Prosperi Book 2017 Springer International Publishing AG 2017 Targeted Therap [打印本頁(yè)] 作者: Maudlin 時(shí)間: 2025-3-21 19:37
書(shū)目名稱(chēng)Resistance to Targeted Therapies in Breast Cancer影響因子(影響力)
書(shū)目名稱(chēng)Resistance to Targeted Therapies in Breast Cancer影響因子(影響力)學(xué)科排名
書(shū)目名稱(chēng)Resistance to Targeted Therapies in Breast Cancer網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱(chēng)Resistance to Targeted Therapies in Breast Cancer網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱(chēng)Resistance to Targeted Therapies in Breast Cancer被引頻次
書(shū)目名稱(chēng)Resistance to Targeted Therapies in Breast Cancer被引頻次學(xué)科排名
書(shū)目名稱(chēng)Resistance to Targeted Therapies in Breast Cancer年度引用
書(shū)目名稱(chēng)Resistance to Targeted Therapies in Breast Cancer年度引用學(xué)科排名
書(shū)目名稱(chēng)Resistance to Targeted Therapies in Breast Cancer讀者反饋
書(shū)目名稱(chēng)Resistance to Targeted Therapies in Breast Cancer讀者反饋學(xué)科排名
作者: Concerto 時(shí)間: 2025-3-21 21:10 作者: 單片眼鏡 時(shí)間: 2025-3-22 00:50
Resistance to HER2-Targeted Therapy,pressed in 20–25% of breast cancers and high expression is associated with poor clinical outcomes if not treated with an HER2-targeted drug. Although HER2 does not have a known extracellular ligand, HER2 is the preferred heterodimerization partner for the other HER-family receptors and HER2-containi作者: amputation 時(shí)間: 2025-3-22 06:16
Endocrine Resistance and Breast Cancer Stem Cells: The Inflammatory Connection that Could Lead to Nstrogen receptor (ER) and will be treated with endocrine therapy, such as tamoxifen or aromatase inhibitors. Interfering with ER action via endocrine therapies has been a mainstay of breast cancer treatment for more than a century. But despite its proven success, the onset of endocrine resistance li作者: 無(wú)孔 時(shí)間: 2025-3-22 09:56
EGFR Resistance,ll growth by inhibiting epidermal growth factor receptors (EGFRs). Targeting the EGFR has been intensely pursued in the breast cancer, with mixed results and challenges with respect to treatment resistance emerging over time. The resistance to EGFR inhibitors is now well recognized due its high prev作者: incite 時(shí)間: 2025-3-22 14:46
Targeting FGFR for the Treatment of Breast Cancer,f at least 5 distinct subtypes of the disease. Importantly, breast cancer subtyping can predict for tumor recurrence and drives the clinical application of endocrine and human epidermal growth factor receptor 2 (Her2)-targeted therapies. Recent studies have revealed that these subtypes of breast can作者: 腐蝕 時(shí)間: 2025-3-22 17:14 作者: LOPE 時(shí)間: 2025-3-22 22:08
Future Paradigm of Breast Cancer Resistance and Treatment,detecting the disease progression and relapse. Resistance to therapy is not only common but expected. Multidisciplinary joint efforts are required in making necessary progress with breast cancer treatment. With the recent advances in multiplex genotyping and high-throughput genomic sequencing techno作者: Customary 時(shí)間: 2025-3-23 01:53
Book 2017ncer (i.e., EGFR and Wnt signaling). We have also provided an overview of standard of care as an introduction into the importance of targeted therapy. It is our hope that this volume gives an insight into the landscape of breast cancer treatment, the challenges of targeted therapy, and a glimpse into the future of breast cancer therapy..作者: Orthodontics 時(shí)間: 2025-3-23 07:04
Book 2017t ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast cancer (i.e., EGFR and Wnt signaling). We have also provided an overview of standard of care as an introduction into the importance of targeted therapy.作者: indignant 時(shí)間: 2025-3-23 11:16 作者: 粗野 時(shí)間: 2025-3-23 15:37
2196-5501 s used to treat ER+ or Her2+ breast cancers (i.e. Tamoxifen .We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signalin作者: MEET 時(shí)間: 2025-3-23 20:14 作者: Incumbent 時(shí)間: 2025-3-23 23:03 作者: STENT 時(shí)間: 2025-3-24 05:52 作者: 牛馬之尿 時(shí)間: 2025-3-24 10:11
Targeting FGFR for the Treatment of Breast Cancer,candidates for any currently approved molecular therapies and they are left with suboptimal, highly cytotoxic chemotherapies as treatment options. Therefore, recent research has focused on identifying the molecular drivers of TNBC and metastatic breast cancer that has undergone subtype switching and作者: 絆住 時(shí)間: 2025-3-24 11:22
Targeted Therapies in Breast Cancer,th increased cell proliferation and mammosphere production, while inhibition has been shown to minimize these effects in cancerous cells. The PI3K pathway is an essential component of intracellular signaling that is frequently dysregulated in tumors. Poly(ADP-ribose) polymerases (PARP) are implicate作者: 為敵 時(shí)間: 2025-3-24 17:18
Future Paradigm of Breast Cancer Resistance and Treatment, a resistant cell. One of the examples of these molecularly targeted biomarker therapies in HER2/neu-positive breast cancer is HER2/neu blockage. Following endocrine therapy, the occurrence of secondary resistance, such as ESR1 mutations, poses a significant challenge. Drugs like lapatinib may be ef作者: 白楊 時(shí)間: 2025-3-24 22:02 作者: 地殼 時(shí)間: 2025-3-25 00:31 作者: CHURL 時(shí)間: 2025-3-25 04:45 作者: delegate 時(shí)間: 2025-3-25 09:04
Irida Kastrati appear pedantic and formalistic, suppressing the very powerful and dynamic character of this old ?eld, which at the same time so young. Geometry is a ?eld of mathematical insight, research, history and source of artistic inspiration. And not least important, an integral part of our common cultural heritage.978-3-642-42392-5978-3-642-14441-7作者: obscurity 時(shí)間: 2025-3-25 12:49
Laura Bourdeanu PhD,Ellen Liu MSN,Suzanne Brint MSN,David Langdon MD appear pedantic and formalistic, suppressing the very powerful and dynamic character of this old ?eld, which at the same time so young. Geometry is a ?eld of mathematical insight, research, history and source of artistic inspiration. And not least important, an integral part of our common cultural heritage.978-3-642-42392-5978-3-642-14441-7作者: agonist 時(shí)間: 2025-3-25 19:13
Remah Ali,Saeed S. Akhand,Michael K. Wendt appear pedantic and formalistic, suppressing the very powerful and dynamic character of this old ?eld, which at the same time so young. Geometry is a ?eld of mathematical insight, research, history and source of artistic inspiration. And not least important, an integral part of our common cultural heritage.978-3-642-42392-5978-3-642-14441-7作者: blackout 時(shí)間: 2025-3-25 20:24 作者: 熔巖 時(shí)間: 2025-3-26 02:13 作者: Perigee 時(shí)間: 2025-3-26 06:44
appear pedantic and formalistic, suppressing the very powerful and dynamic character of this old ?eld, which at the same time so young. Geometry is a ?eld of mathematical insight, research, history and source of artistic inspiration. And not least important, an integral part of our common cultural heritage.978-3-642-42392-5978-3-642-14441-7作者: 評(píng)論性 時(shí)間: 2025-3-26 08:55 作者: 節(jié)省 時(shí)間: 2025-3-26 12:38
https://doi.org/10.1007/978-3-319-70142-4Targeted Therapy; Her2-Targeted Therapy; Hormone Therapy; Angiogenesis; EGFR Inhibition作者: 淘氣 時(shí)間: 2025-3-26 18:33 作者: considerable 時(shí)間: 2025-3-27 00:25
978-3-319-88891-0Springer International Publishing AG 2017作者: Lipoprotein(A) 時(shí)間: 2025-3-27 02:45 作者: Metastasis 時(shí)間: 2025-3-27 08:20 作者: guardianship 時(shí)間: 2025-3-27 12:01
Georges E. Tanios,Matthew E. Burow,Bridgette Collins-Burow,David G. Morrisones with some suggestions for solutions.Includes supplementarThis is a revised edition of the ?rst printing which appeared in 2002. The book is based on lectures at the University of Bergen, Norway.Over the years these lectures have covered many different aspects and facets of the wonderful ?eld of g作者: entail 時(shí)間: 2025-3-27 14:08
Dirk Theile,Gal Lenz,Jamil A. Momand,Susan E. Kanees with some suggestions for solutions.Includes supplementarThis is a revised edition of the ?rst printing which appeared in 2002. The book is based on lectures at the University of Bergen, Norway.Over the years these lectures have covered many different aspects and facets of the wonderful ?eld of g作者: Asymptomatic 時(shí)間: 2025-3-27 20:29 作者: 直覺(jué)好 時(shí)間: 2025-3-27 23:31 作者: limber 時(shí)間: 2025-3-28 04:22
Remah Ali,Saeed S. Akhand,Michael K. Wendtes with some suggestions for solutions.Includes supplementarThis is a revised edition of the ?rst printing which appeared in 2002. The book is based on lectures at the University of Bergen, Norway.Over the years these lectures have covered many different aspects and facets of the wonderful ?eld of g
